Another phase III, randomized, open-label, non-inferiority, head-to-head trial, AWARD-6, evaluated dulaglutide (1.5 mg) versus liraglutide (1.8 mg) in patients with T2DM
People who do not match those groups, or who match a contraindication, should not use it without close clinician oversight and in some cases, should not use it at all
Andan may adjust your dose accordingly
Everything is included upfront
Many users find that just logging meals for three to four weeks teaches them enough about portion sizes and protein content that they can maintain their diet intuitively afterward
10.7860/JCDR/2022/53256.16055 48 Sanz-CuestaT.Escortell-MayorE.Cura-GonzalezI.Martin-FernandezJ.Riesgo-FuertesR.Garrido-ElustondoS.et al (2020)